Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06982963 | Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease | PHASE2 | RECRUITING | 100 | — | — | Aug 4, 2025 | Feb 28, 2027 | Nov 18, 2025 | 1 | Australia |
Vh:Cd and IEL Composite Scale (VCIEL)
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | FB102 |
| B | EXPERIMENTAL | FB102 |
| C | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| FB102 | BIOLOGICAL | FB102 (10 mg/kg induction doses and 3 mg/kg or 5 mg/kg maintenance doses) or placebo arms in a 2:2:1 ratio. |
| Placebo | OTHER | Placebo |
Inclusion Criteria: 1. Men and women aged 18 to 70 years at Screening. 2. Has documented diagnosis of CeD confirmed by intestinal biopsy and positive celiac serology at least 12 months prior to Screening (intestinal biopsy and serology do not have to be performed concurrently). 3. Body mass index (...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | Amlitelimab |
| Forte Biosciences Inc. | FBRX | 1 | PHASE2 | FB102 |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 1 | PHASE2 | TEV-53408 |
| Barinthus Biotherapeutics plc Sponsored ADR | BRNS | 1 | EARLY_PHASE1 | VTP-1000 |
| TScan Therapeutics, Inc. | TCRX | 1 | — | Undisclosed |